Cargando…

Prognostic and predictive value of PDL1 expression in breast cancer

Expression of programmed cell death receptor ligand 1 (PDL1) has been scarcely studied in breast cancer. Recently PD1/PDL1-inhibitors have shown promising results in different carcinomas with correlation between PDL1 tumor expression and responses. We retrospectively analyzed PDL1 mRNA expression in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabatier, Renaud, Finetti, Pascal, Mamessier, Emilie, Adelaide, José, Chaffanet, Max, Ali, Hamid Raza, Viens, Patrice, Caldas, Carlos, Birnbaum, Daniel, Bertucci, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467160/ https://www.ncbi.nlm.nih.gov/pubmed/25669979

Ejemplares similares

Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
por: Sabatier, Renaud, et al.
Publicado: (2014)

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

Prognostic value of PDL1 expression in pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2016)

CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression
por: Boudin, Laurys, et al.
Publicado: (2022)

Kinome expression profiling and prognosis of basal breast cancers
por: Sabatier, Renaud, et al.
Publicado: (2011)

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
por: Bertucci, François, et al.
Publicado: (2018)

WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2021)

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers
por: de Nonneville, Alexandre, et al.
Publicado: (2019)

Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2011)

Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype
por: de Nonneville, Alexandre, et al.
Publicado: (2023)

Comparative genomic analysis of primary tumors and metastases in breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

Validation and comparison of the molecular classifications of pancreatic carcinomas
por: Birnbaum, David J., et al.
Publicado: (2017)

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

“Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity
por: Mamessier, Emilie, et al.
Publicado: (2012)

Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial
por: Sabatier, Renaud, et al.
Publicado: (2022)

Loss, mutation and deregulation of L3MBTL4 in breast cancers
por: Addou-Klouche, Lynda, et al.
Publicado: (2010)

A seven-gene prognostic model for platinum-treated ovarian carcinomas
por: Sabatier, R, et al.
Publicado: (2011)

A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases
por: Tyran, Marguerite, et al.
Publicado: (2019)

Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value
por: Doghri, Raoudha, et al.
Publicado: (2017)

High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes
por: Bekhouche, Ismahane, et al.
Publicado: (2011)

Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease
por: Mari, Roxane, et al.
Publicado: (2019)

Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial
por: Billon, Emilien, et al.
Publicado: (2022)

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
por: Bertucci, François, et al.
Publicado: (2021)

Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?
por: Aulas, Anaïs, et al.
Publicado: (2020)

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
por: Bertucci, François, et al.
Publicado: (2023)

The MonarchE trial: improving the clinical outcome in HR(+)/HER2(−) early breast cancer: recent results and next steps
por: Bertucci, François, et al.
Publicado: (2023)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

Genome profiling of ERBB2-amplified breast cancers
por: Sircoulomb, Fabrice, et al.
Publicado: (2010)

PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma
por: Birnbaum, David Jeremie, et al.
Publicado: (2023)

Low cholesterol biosynthesis favors epithelial‐to‐mesenchymal transition maintenance and influences tumor molecular subtyping and disease‐free survival in colon cancer patients
por: Aulas, Anaïs, et al.
Publicado: (2022)

The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study
por: Sabatier, Renaud, et al.
Publicado: (2022)

ZNF703 mRNA-Targeting Antisense Oligonucleotide Blocks Cell Proliferation and Induces Apoptosis in Breast Cancer Cell Lines
por: Udu-Ituma, Sandra, et al.
Publicado: (2023)

Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients
por: Lopresti, Alexia, et al.
Publicado: (2022)

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer
por: Guerin, Mathilde, et al.
Publicado: (2018)

8q24 Cancer Risk Allele Associated with Major Metastatic Risk in Inflammatory Breast Cancer
por: Bertucci, François, et al.
Publicado: (2012)

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
por: Bertucci, François, et al.
Publicado: (2021)

Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study
por: Gonçalves, Anthony, et al.
Publicado: (2016)

Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling
por: Cornen, Stéphanie, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a7lell38ov0o9acjj9cblktjer